Stroke: working toward a prioritized world agenda
- PMID: 20636706
- PMCID: PMC3712839
- DOI: 10.1111/j.1747-4949.2010.00442.x
Stroke: working toward a prioritized world agenda
Abstract
Background and purpose: The aim of the Synergium was to devise and prioritize new ways of accelerating progress in reducing the risks, effects, and consequences of stroke.
Methods: Preliminary work was performed by seven working groups of stroke leaders followed by a synergium (a forum for working synergistically together) with approximately 100 additional participants. The resulting draft document had further input from contributors outside the synergium.
Results: Recommendations of the Synergium are: Basic Science, Drug Development and Technology: There is a need to develop: (1) New systems of working together to break down the prevalent 'silo' mentality; (2) New models of vertically integrated basic, clinical, and epidemiological disciplines; and (3) Efficient methods of identifying other relevant areas of science. Stroke Prevention: (1) Establish a global chronic disease prevention initiative with stroke as a major focus. (2) Recognize not only abrupt clinical stroke, but subtle subclinical stroke, the commonest type of cerebrovascular disease, leading to impairments of executive function. (3) Develop, implement and evaluate a population approach for stroke prevention. (4) Develop public health communication strategies using traditional and novel (eg, social media/marketing) techniques. Acute Stroke Management: Continue the establishment of stroke centers, stroke units, regional systems of emergency stroke care and telestroke networks. Brain Recovery and Rehabilitation: (1) Translate best neuroscience, including animal and human studies, into poststroke recovery research and clinical care. (2) Standardize poststroke rehabilitation based on best evidence. (3) Develop consensus on, then implementation of, standardized clinical and surrogate assessments. (4) Carry out rigorous clinical research to advance stroke recovery. Into the 21st Century: Web, Technology and Communications: (1) Work toward global unrestricted access to stroke-related information. (2) Build centralized electronic archives and registries. Foster Cooperation Among Stakeholders (large stroke organizations, nongovernmental organizations, governments, patient organizations and industry) to enhance stroke care. Educate and energize professionals, patients, the public and policy makers by using a 'Brain Health' concept that enables promotion of preventive measures.
Conclusions: To accelerate progress in stroke, we must reach beyond the current status scientifically, conceptually, and pragmatically. Advances can be made not only by doing, but ceasing to do. Significant savings in time, money, and effort could result from discontinuing practices driven by unsubstantiated opinion, unproven approaches, and financial gain. Systematic integration of knowledge into programs coupled with careful evaluation can speed the pace of progress.
Conflict of interest statement
G.A.D.a received other research support from Boehringer Ingelheim (BI) and Sanofi-Aventis; Consultant/Advisory Board for BI, Servier, Sanofi-Aventis, Bristol Myer Squibb. P.B.G. received Speakers Honoraria from BI; Consultant/Advisory Board for Bayer, Abott, Takeda.S.C.C.d, h received research grant from GlaxoSmith-Kline (GSK) and Stem Cell Therapeutics; Consultant/Advisory Board for GSK, Stem Cell Therapeutics, Johnson and Johnson, Photothera (all significant) and Pfizer Inc, Allergan Inc, Grupo Ferrer SA (all modest). M.K.e,h received Honoraria from BI, PAION AG, Servier, Forest Research Laboratories Inc, Neurobiological Technologies Inc, and Lund beck AS for participating in the Steering Committee meetings of ProFESS, PERFORM, ANCROD, and all ECASS, DIAS and CEPO trials, and for giving lectures in national and international meetings sponsored by the above mentioned companies and Sanofi-Aventis and BMS; Consultant/Advisory Board for BI, PAION AG,Servier, Forest Research Laboratories Inc, Neurobiological Technologies Inc, and Lund beck AS.B.E.S.a is an employee of Novo Nordisk. K.L.F.b received IRIS trial funding through National Institute of Neurological Disorders and Stroke (NINDS). G.J.H.b received Speakers Honoraria from Pfizer, Sanofi-Aventis; Consultant/Advisory Board for BI, Sanofi-Aventis. J.C.M. b participated/is currently participating in clinical trials of antidementia drugs sponsored by Elan, Eli Lilly and Company, Wyeth; Consultant/ Speaking Honoraria from AstraZeneca, Bristol-Myers Squibb, Genentech, Lilly, Merck, Novartis, Pfizer, Schering Plough, Wyeth Elan. R.L.S.b received a research grant from NINDS (Northern Manhattan Stroke Study). Y.W.b is CEO and serves as/on Consultant/Advisory Board of InTouch Health, Goleta, Calif. G.A.F. c: payment to institution from companies undertaking stroke research including Lund beck, Mitsubishi, PAION, BI for trial related activities; payment to institution for administrative support of UK SITS database, BI; personal payment for educational lectures (modest) and advisory board (modest), BI, Lund beck. S.C.O.M.c received lecture fees from BI.J.S.c is employed at University of California; received research grants from National Institutes of Health (NIH); Consultant/Advisory Board of Talacris, Syquil, EV3, AGA, Brainsbok; University of California receives research grants from NIH and hundreds of industry companies; University of California has patent interest in the Merci retriever. M.M.B. d is an employee of Pfizer Inc. P. D. d is an employee of Duke University. L.E.d is an employee of GSK.S.F.d is an employee of Biotrofix, Inc and Massachusetts General Hospital (significant); has ownership interest in Biotrofix, Inc; and Consultant/Advisory Board for Pfizer, GSK, Johnson and Johnson, Acorda, and Lanthers. J.K. d is employed at University of Florida. L.H.S.e, Consultant/Advisory Board for Massachusetts Department of Public Health and Phreesia Inc. B.T.e is employed at Southern IL Healthcare. N.W.e is employed at Karolinska Institute. L.K.W.e is employed at Chinese University of Hong Kong. S.P.f is employed at the American Heart Association. V.H.,W.H. c,h,M.F.f,h, M.B.g,h,A M B a, E.H.L.a, P.M.R.b, S.C.S.b, A.B.c, C.I.c, M.B.d, T.A.J.d, L.K. d, R.N. d, R.T.d, C.W.d, M.P.G.e, W.-D.H. e,O. S. e, Y.S.e, A.H.f, B.N.f, N.M.B.g,S.M.D.g,L.B.G.g,D.L.g,J.T.g,M.K.b,V.S.c,and B.D.e have no conflicts to report.
Figures
Similar articles
-
Stroke: working toward a prioritized world agenda.Stroke. 2010 Jun;41(6):1084-99. doi: 10.1161/STROKEAHA.110.586156. Stroke. 2010. PMID: 20498453 Free PMC article. Review.
-
Stroke: working toward a prioritized world agenda.Cerebrovasc Dis. 2010;30(2):127-47. doi: 10.1159/000315099. Epub 2010 May 24. Cerebrovasc Dis. 2010. PMID: 20516682 Free PMC article.
-
The future of Cochrane Neonatal.Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12. Early Hum Dev. 2020. PMID: 33036834
-
How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?Int J Evid Based Healthc. 2008 Mar;6(1):78-110. doi: 10.1111/j.1744-1609.2007.00098.x. Int J Evid Based Healthc. 2008. PMID: 21631815
-
Critical Care Network in the State of Qatar.Qatar Med J. 2019 Nov 7;2019(2):2. doi: 10.5339/qmj.2019.qccc.2. eCollection 2019. Qatar Med J. 2019. PMID: 31763205 Free PMC article.
Cited by
-
Rationale for Intervention and Dose Is Lacking in Stroke Recovery Trials: A Systematic Review.Stroke Res Treat. 2018 Oct 30;2018:8087372. doi: 10.1155/2018/8087372. eCollection 2018. Stroke Res Treat. 2018. PMID: 30515288 Free PMC article. Review.
-
Pipeline for Analyzing Lesions After Stroke (PALS).Front Neuroinform. 2018 Sep 24;12:63. doi: 10.3389/fninf.2018.00063. eCollection 2018. Front Neuroinform. 2018. PMID: 30319385 Free PMC article.
-
Continuous Tissue Plasminogen Activator Infusion Using a Minimally Invasive Irrigating Catheter for the Treatment of Intraparenchymal Hemorrhage Within the Basal Ganglia: Case Reports.Oper Neurosurg. 2022 Dec 1;23(6):e387-e391. doi: 10.1227/ons.0000000000000408. Epub 2022 Sep 14. Oper Neurosurg. 2022. PMID: 36227254 Free PMC article.
-
Effects of Dl-3-n-butylphthalide on Cerebral Ischemia Infarction in Rat Model by Mass Spectrometry Imaging.Int J Mol Sci. 2017 Nov 22;18(11):2451. doi: 10.3390/ijms18112451. Int J Mol Sci. 2017. PMID: 29165327 Free PMC article.
-
Moderating Role of Initiative on the Relationship Between Intrinsic Motivation, and Self-Efficacy on Entrepreneurial Intention.Front Psychol. 2022 Oct 12;13:866869. doi: 10.3389/fpsyg.2022.866869. eCollection 2022. Front Psychol. 2022. PMID: 36312071 Free PMC article.
References
-
- Kannel WB, Wolf PA, Verter J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke.The Framingham study. JAMA. 1970;12:301–310. 214. - PubMed
-
- Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med. 1978;299:53–59. - PubMed
-
- Norris JW, Hachinski VC. Intensive care management of stroke patients. Stroke. 1976;7:573–577. - PubMed
-
- The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischaemic stroke. N Engl J Med. 1995;333:1581–1587. - PubMed
-
- Millikan CH. Stroke: 970–1977. Stroke. 2001;32:3–5. - PubMed